SpaceX Is Nearing Its IPO Price. Time to Buy?

Space Exploration Technologies (SpaceX/SPCX) trades just below its IPO price at about $138 per share, with a $1.8T market cap implying highly priced-in growth. The article flags an extremely elevated valuation—~96x trailing P/S versus bullish forecasts of 108% revenue growth in 2026—implying a much lower ~46x forward P/S if the stock price doesn’t move, and argues the premium is hard to justify versus peers like Micron (12x trailing P/S). Overall, it advises investors to avoid SPCX unless valuation compresses.

Analysis

The key issue is not near-term business momentum; it is duration risk. A stock priced for multiple years of flawless execution becomes extremely sensitive to any change in discount rates, funding conditions, or the first sign that revenue growth is not translating into durable free cash flow. That makes SPCX less like an operating stock and more like a long-dated call option, where even small disappointments can trigger large multiple compression.

Second-order effects extend beyond SPCX itself. If the market starts questioning this premium, late-stage private-growth and satellite/space adjacent names can reprice lower simply because the financing bar moves up. Public investors may also rotate toward cheaper “same-growth, lower-multiple” exposures, which supports relative-value longs in businesses with visible cash generation rather than story-driven compounding.

The contrarian view is scarcity: a genuine platform monopoly can sustain a premium longer than screen-based valuation models imply, especially if rates fall and private-market risk appetite reopens. That said, the burden of proof is high; the thesis only works if operating metrics keep outrunning the valuation gap, not just if the company remains strategically important. The market is likely underestimating how quickly a premium can unwind once early holders start treating liquidity as the real product.

Key Decisions for Investors

• If SPCX is accessible, initiate a 3-6 month put spread on strength rather than chasing weakness; target 15-25% downside if the post-IPO premium begins to normalize, with premium paid as defined risk.